GSK plc (LON:GSK) Receives Average Recommendation of “Hold” from Analysts

Shares of GSK plc (LON:GSK) have earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is GBX 1,917.86.

A number of research analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 price target on shares of GSK in a research note on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a report on Thursday, January 15th. UBS Group restated a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a report on Friday, January 23rd. Finally, Berenberg Bank upped their price target on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th.

GSK Trading Down 0.6%

LON GSK opened at GBX 2,193 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,282. The business has a 50 day moving average price of GBX 1,930.55 and a 200-day moving average price of GBX 1,732.69. The company has a market cap of £88.48 billion, a price-to-earnings ratio of 16.49, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jonathan Symonds purchased 2,500 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The shares were acquired at an average cost of GBX 2,114 per share, for a total transaction of £52,850. Also, insider Wendy Becker acquired 3,334 shares of GSK stock in a transaction on Friday, February 20th. The stock was purchased at an average cost of GBX 2,219 per share, with a total value of £73,981.46. Insiders have bought 7,931 shares of company stock valued at $16,480,489 in the last three months. 0.20% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.